Your browser is no longer supported. Please, upgrade your browser.
Settings
AFMD Affimed N.V. daily Stock Chart
AFMD [NASD]
Affimed N.V.
Index- P/E- EPS (ttm)-0.17 Insider Own8.15% Shs Outstand61.91M Perf Week21.76%
Market Cap197.49M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float57.70M Perf Month-7.00%
Income-10.60M PEG- EPS next Q-0.14 Inst Own38.30% Short Float7.71% Perf Quarter-20.45%
Sales39.00M P/S5.06 EPS this Y53.40% Inst Trans-8.60% Short Ratio4.52 Perf Half Y-16.49%
Book/sh0.77 P/B4.14 EPS next Y15.50% ROA-11.20% Target Price8.15 Perf Year41.78%
Cash/sh1.73 P/C1.84 EPS next 5Y- ROE-22.70% 52W Range1.40 - 7.35 Perf YTD2.57%
Dividend- P/FCF4.13 EPS past 5Y22.80% ROI-43.50% 52W High-56.60% Beta2.95
Dividend %- Quick Ratio3.20 Sales past 5Y36.10% Gross Margin- 52W Low127.86% ATR0.21
Employees110 Current Ratio3.20 Sales Q/Q2034.00% Oper. Margin-30.60% RSI (14)51.54 Volatility10.13% 7.01%
OptionableYes Debt/Eq0.10 EPS Q/Q119.80% Profit Margin-27.30% Rel Volume0.83 Prev Close3.32
ShortableYes LT Debt/Eq0.02 EarningsMay 22 BMO Payout- Avg Volume984.34K Price3.19
Recom1.50 SMA204.15% SMA50-6.14% SMA200-14.28% Volume821,847 Change-3.92%
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Jul-14-17Initiated SunTrust Buy $7
Aug-12-16Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15Initiated Laidlaw Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Sep-09-15Initiated Jefferies Hold
Aug-06-15Reiterated Oppenheimer Outperform $14 → $19
Jun-22-15Reiterated Jefferies Buy $12 → $16
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-12-19 07:55AM  Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT Thomson Reuters StreetEvents
05:30AM  Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland GlobeNewswire
Jun-04-19 04:01PM  Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
Jun-03-19 05:00AM  Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagens Patented Mammalian Expression Technology GlobeNewswire
May-29-19 05:00AM  Affimed to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-23-19 02:25PM  Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1 Zacks
May-22-19 03:23PM  Affimed N.V. (AFMD) Q1 2019 Earnings Call Transcript Motley Fool -6.93%
08:45AM  Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates Zacks
07:58AM  Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% MarketWatch
07:30AM  Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress GlobeNewswire
May-21-19 02:16PM  Affimed Q1 Earnings Preview Benzinga
May-16-19 05:00AM  Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019 GlobeNewswire
May-14-19 10:30AM  Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
May-13-19 09:17AM  What's in Store for Affimed (AFMD) This Earnings Season? Zacks
Apr-30-19 09:00AM  Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade Zacks
Apr-27-19 09:16AM  If You Had Bought Affimed (NASDAQ:AFMD) Shares A Year Ago You'd Have Made 62% Simply Wall St.
Apr-17-19 04:05PM  Affimed Provides Regulatory Update on AFM11 Clinical Program GlobeNewswire
Apr-09-19 08:48AM  Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Apr-01-19 02:35PM  Edited Transcript of AFMD earnings conference call or presentation 27-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting GlobeNewswire
Mar-27-19 01:49PM  Affimed N.V. (AFMD) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:30AM  Affimed Reports 2018 Financial Results and Operational Progress GlobeNewswire
Mar-20-19 05:00AM  Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019 GlobeNewswire
Mar-19-19 07:40AM  The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed Benzinga +6.89%
05:00AM  Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity GlobeNewswire
Mar-12-19 10:30AM  Will Affirmed Therapeutics (AFMD) Report Negative Q4 Earnings? What You Should Know Zacks +9.92%
Feb-27-19 05:01PM  Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019 GlobeNewswire
Feb-21-19 07:30AM  Affimed to Present at Upcoming Investor Conferences GlobeNewswire
Feb-19-19 02:34PM  Trading Notes for Select Stocks TheStreet.com
Jan-04-19 08:30AM  Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.54%
Dec-24-18 08:50AM  Do Options Traders Know Something About Affimed (AFMD) Stock We Don't? Zacks
Dec-23-18 07:53AM  Affimed NV (AFMD): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-07-18 06:19PM  Edited Transcript of AFMD earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -5.21%
11:30AM  Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day GlobeNewswire
Dec-03-18 11:30AM  Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors GlobeNewswire
Nov-28-18 05:00AM  Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City GlobeNewswire
Nov-26-18 10:36AM  My Stock of the Week: Affirmed N.V. TheStreet.com
Nov-23-18 02:06PM  Our Take On Affimed NVs (NASDAQ:AFMD) CEO Salary Simply Wall St.
Nov-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +8.68%
Nov-09-18 09:18AM  Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Nov-08-18 05:35AM  Affimed to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire +6.57%
Nov-07-18 11:05AM  Affirmed Therapeutics (AFMD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:31AM  Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress GlobeNewswire
Nov-01-18 09:16AM  Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting GlobeNewswire +17.78%
Oct-31-18 06:01AM  Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018 GlobeNewswire +6.42%
Oct-10-18 10:07AM  Company News For Oct 10, 2018 Zacks
Oct-09-18 10:01AM  Affimed Down After Clinical Hold on Two Early-Stage Studies Zacks -24.41%
09:16AM  [$$] Stocks to Watch: Alphabet, Exxon, Papa John's, Tesla The Wall Street Journal
08:43AM  Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
08:21AM  Stocks making the biggest move premarket: TSLA, PZZA, MSFT, WMT & more CNBC
08:03AM  The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial Benzinga
Oct-08-18 05:05PM  After-hours buzz: TSLA, EW & more CNBC +10.77%
04:49PM  Affimed shares plunge as cancer-drug studies put on hold after death MarketWatch
04:15PM  Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold GlobeNewswire
Sep-12-18 10:30AM  Immuno Oncology & Targeted Therapy Companies Set to Breakout ACCESSWIRE -5.00%
Aug-31-18 07:52AM  Edited Transcript of AFMD earnings conference call or presentation 8-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-30-18 03:48PM  Here's Why Affimed Stock Collapsed Today Motley Fool -13.82%
03:41PM  Affimed (AFMD) Surges on Collaboration Contract with Roche (revised) Zacks
08:33AM  Affimed (AFMD) Soars: Stock Adds 10.8% in Session Zacks
05:33AM  Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference GlobeNewswire
Aug-29-18 11:20AM  Affimed (AFMD) Surges On Collaboration Contract With Roche Zacks +10.81%
09:23AM  Up 246%: Is This Small-Cap Biotech Stock Still a Buy? Motley Fool
08:05AM  Affimed Shares Leap on News of Genentech Deal, Analysts Review and Target ACCESSWIRE
07:54AM  The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent Benzinga
Aug-28-18 10:25AM  Biotech Stocks Take Aim At New Highs In August 2018 ACCESSWIRE +246.88%
10:12AM  Affimed Shares Soar On $5B Collaboration With Roche's Genentech Benzinga
08:54AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 05:12PM  Affimed shares more than double after $96 million Genentech agreement MarketWatch
04:10PM  Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets GlobeNewswire
Aug-08-18 08:45AM  Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:31AM  Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress GlobeNewswire
06:30AM  Affimed N.V. to Host Earnings Call ACCESSWIRE
Aug-03-18 12:26PM  Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call GlobeNewswire
Jul-26-18 07:20AM  Free Technical Research on Advaxis and Three More Biotech Equities ACCESSWIRE
Jul-13-18 08:46AM  Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Jun-28-18 10:34AM  MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens GlobeNewswire
Jun-15-18 10:56AM  Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data Benzinga -15.31%
05:00AM  Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA GlobeNewswire
Jun-11-18 10:34AM  3 Biotechs with Upcoming Data to Watch SmarterAnalyst
07:40AM  Todays Free Research Reports Coverage on Agenus and Three More Biotech Stocks ACCESSWIRE
May-30-18 05:00AM  Affimed to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-24-18 08:32AM  Edited Transcript of AFMD earnings conference call or presentation 15-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-18-18 04:01PM  Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
May-15-18 09:55AM  Does Affimed NV. (NASDAQ:AFMD) Fall With The Market? Simply Wall St.
07:45AM  Affimed Reports Financial Results for First Quarter 2018 GlobeNewswire
06:45AM  Affimed N.V. to Host Earnings Call ACCESSWIRE
May-08-18 05:00AM  Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call GlobeNewswire
May-03-18 05:00AM  Affimed to Present at Deutsche Bank's 43rd Annual Health Care Conference GlobeNewswire
05:00AM  Affimed Introduces ROCK(TM) Platform for Tailored Immune Cell Engagers GlobeNewswire
Apr-19-18 07:40AM  Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugens BAY 1905254 Efficacy in Cancer Immunotherapy ACCESSWIRE
Apr-16-18 02:01PM  Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy GlobeNewswire
Mar-20-18 09:16PM  Edited Transcript of AFMD earnings conference call or presentation 20-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:31AM  Affimed Reports Financial Results for Fourth Quarter and Year End 2017 GlobeNewswire
06:30AM  Affimed N.V. to Host Earnings Call ACCESSWIRE
Mar-19-18 05:58PM  Has Affimed NV. (NASDAQ:AFMD) Improved Earnings Growth In Recent Times? Simply Wall St. -6.98%
08:49AM  Why Earnings Season Could Be Great for Affimed (AFMD) Zacks
06:01AM  Affimed Appoints Dr. Leila Alland as Chief Medical Officer GlobeNewswire
Mar-15-18 04:01AM  Affimed to Present Data on AFM24 at AACR Annual Meeting 2018 GlobeNewswire
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.